Does Rallies show 13F holders for APGE?

Yes. Rallies tracks hedge fund and 13F ownership data for APGE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is APGE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APGE. It does not provide personalized investment advice.

APGE (Apogee Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Apogee Therapeutics, Inc. Common Stock (APGE) is a publicly traded Healthcare sector company. As of May 21, 2026, APGE trades at $81.49 with a market cap of $5.94B and a P/E ratio of -19.12. APGE moved +4.09% today. Year to date, APGE is +5.01%; over the trailing twelve months it is +101.76%. Its 52-week range spans $26.20 to $95.32. Analyst consensus is strong buy with an average price target of $122.25. Rallies surfaces APGE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns APGE stock?

Hedge funds tracked by Rallies that own APGE include Orbimed Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Apogee Therapeutics, Inc. Common Stock.

APGE Key Metrics

Key financial metrics for APGE
Metric	Value
Price	$81.49
Market Cap	$5.94B
P/E Ratio	-19.12
EPS	$-4.22
Dividend Yield	0.00%
52-Week High	$95.32
52-Week Low	$26.20
Volume	382
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-255.84M
Gross Margin	0.00%

Top Hedge Funds Holding APGE

Orbimed Advisors holds 379.13K shares of APGE, changed +0.00% as of Sep 30, 2024.

Latest APGE News

Apogee Therapeutics rises after Q1 2026 results and pipeline update issued May 11 — May 11, 2026
Apogee’s Zumilokibart Achieves 85% Week 16 Maintenance at Six-Month Dosing, Secures $403M — May 11, 2026
Apogee Therapeutics climbs on new Buy initiation ahead of key Q2 dermatitis readout — May 4, 2026
Apogee Therapeutics slides as recent $350M equity offering overhang weighs on shares — Apr 29, 2026
Apogee Therapeutics slips as recent $350M follow-on offering overhang weighs on shares — Apr 26, 2026

Recent APGE Insider Trades

HENDERSON MICHAEL THOMAS sold 18.66K (~$1.53M) on May 13, 2026.
HENDERSON MICHAEL THOMAS sold 1.34K (~$110.74K) on May 13, 2026.
Dambkowski Carl sold 3.70K (~$310.50K) on May 6, 2026.

APGE Analyst Consensus

15 analysts cover APGE: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.25.

Common questions about APGE

Who owns APGE stock?: Hedge funds tracked by Rallies that own APGE include Orbimed Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Apogee Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for APGE?: Yes. Rallies tracks hedge fund and 13F ownership data for APGE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is APGE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APGE. It does not provide personalized investment advice.